(Q33338666)

25 July 2017

title

Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (English)

1 reference

25 July 2017

1 reference

F Cabanillas

9

0 references

author name string

A Younes

1

1 reference

25 July 2017

H A Preti

2

1 reference

25 July 2017

F B Hagemeister

3

1 reference

25 July 2017

P McLaughlin

4

1 reference

25 July 2017

J E Romaguera

5

1 reference

25 July 2017

M A Rodriguez

6

1 reference

25 July 2017

B I Samuels

7

1 reference

25 July 2017

J L Palmer

8

1 reference

25 July 2017

publication date

1 July 2001

1 reference

25 July 2017

1 reference

25 July 2017

volume

12

1 reference

25 July 2017

issue

7

1 reference

25 July 2017

page(s)

923-927

1 reference

A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011172215216

7 January 2021

ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011172215216

7 January 2021

Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011172215216

7 January 2021

Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011172215216

7 January 2021

Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011172215216

7 January 2021

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011172215216

7 January 2021

Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011172215216

7 January 2021

Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011172215216

7 January 2021

Paclitaxel for the treatment of lymphoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011172215216

7 January 2021

EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011172215216

7 January 2021

Identifiers

DOI

10.1023/A:1011172215216

1 reference

25 July 2017

1 reference